Lately a new player has come onto the market to challenge the well known brand Botox, an Allergan product. Botox has mostly dominated the non-surgical aesthetics market in the US, with few real competitors. Up until now the only real alternative to Botox in the US has been Dysport, though many doctors have refrained from utilizing this product for facial aesthetic procedures due to some proof showing that the drug tends to exhibit more local spread.
Merz, a German pharma company, is the manufacturer of Xeomin, a botulinum toxin medication. Xeomin has been commonly used in the UK and Europe and enjoyed by consultants and clients alike. Last year in 2011, Merz announced that the FDA had authorized Xeomin for clinical use in the States and that Xeomin would be publically released in mid-2012. This fact is great news for aesthetics in the US!
While in the US Xeomin is a comparatively unknown product it has many edges over the more reknowned product Botox. Botox must be either stored in a fridge or frozen before reconstitution and is very sensitive to temperature extremes as well as to agitation. For example, when preparing Botox for use, medical practitioners must take care to insert the water for injection slowly, since rapid insertion could render the product inactive.
Xeomin,as opposed to Botox, is a much more resilient medication. A significant edge over Botox is that Xeomin can be kept at 70 degrees and so doesn’t need special storage techniques. In addition Xeomin is a lot less sensitive to agitation. This means that on the part of the clinic less botulinum toxin will be damaged due to poor handling.
In contrast to the other alternative to Botox, Xeomin is far more like Botox in terms of its mechanism of action. Xeomin injections usually remain localized, which means potentially less side effects connected with local spread. Another major advantage is that the units used are the same as the units used by Botox, in constrast to Dysport where the units aren’t matching and can often be a little confusing for doctors.
Also, if the American marketplace follows the European Union, the arrival of Xeomin will cause the cost of botulinum toxin products to come down. Nowadays the going price of Botox in the USA has a tendency to be around $9-12 per unit, while the price in Great Britain is cheaper at around $7-8 per unit.
Therefore the impending penetration of Xeomin into the United States market place will be a good thing for both clients as well as aesthetic clinics.
Botox Course runs the #1 injection course for medical practitioners to instruct them how to inject Botox and start succesful aesthetic day spas. As well as the Injection Course, physicians can learn skin filler injection methodologies and chemical peeling techniques.
